BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 28927521)

  • 1. When the guardian sleeps: Reactivation of the p53 pathway in cancer.
    Merkel O; Taylor N; Prutsch N; Staber PB; Moriggl R; Turner SD; Kenner L
    Mutat Res Rev Mutat Res; 2017 Jul; 773():1-13. PubMed ID: 28927521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
    Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
    J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
    Toledo F; Wahl GM
    Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Update on MDMX and Dual MDM2/X Inhibitors.
    Espadinha M; Barcherini V; Lopes EA; Santos MMM
    Curr Top Med Chem; 2018; 18(8):647-660. PubMed ID: 29866007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [NEGATIVE REGULATORS OF TUMOR SUPPRESSOR P53 IN THE CONTEXT OF ANTICANCER THERAPY].
    Shuvalov OY; Fedorova OA; Petukhov AV; Daks AA; Vasilieva EA; Grigorieva TA; Ivanov GS; Barlev NA
    Tsitologiia; 2015; 57(12):847-54. PubMed ID: 26995961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of p53: a collaboration between Mdm2 and Mdmx.
    Pei D; Zhang Y; Zheng J
    Oncotarget; 2012 Mar; 3(3):228-35. PubMed ID: 22410433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?
    Wade M; Wahl GM
    Mol Cancer Res; 2009 Jan; 7(1):1-11. PubMed ID: 19147532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.
    Toledo F; Wahl GM
    Nat Rev Cancer; 2006 Dec; 6(12):909-23. PubMed ID: 17128209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting p53-MDM2-MDMX loop for cancer therapy.
    Zhang Q; Zeng SX; Lu H
    Subcell Biochem; 2014; 85():281-319. PubMed ID: 25201201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The p53 orchestra: Mdm2 and Mdmx set the tone.
    Wade M; Wang YV; Wahl GM
    Trends Cell Biol; 2010 May; 20(5):299-309. PubMed ID: 20172729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
    Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 as a target for the treatment of cancer.
    Duffy MJ; Synnott NC; McGowan PM; Crown J; O'Connor D; Gallagher WM
    Cancer Treat Rev; 2014 Dec; 40(10):1153-60. PubMed ID: 25455730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.
    Gao C; Xiao G; Piersigilli A; Gou J; Ogunwobi O; Bargonetti J
    Breast Cancer Res; 2019 Jan; 21(1):5. PubMed ID: 30642351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay.
    Golestanian S; Sharifi A; Popowicz GM; Azizian H; Foroumadi A; Szwagierczak A; Holak TA; Amanlou M
    Life Sci; 2016 Jan; 145():240-6. PubMed ID: 26746660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
    Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
    Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
    Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L
    Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas.
    Bozzi F; Conca E; Laurini E; Posocco P; Lo Sardo A; Jocollè G; Sanfilippo R; Gronchi A; Perrone F; Tamborini E; Pelosi G; Pierotti MA; Maestro R; Pricl S; Pilotti S
    Lab Invest; 2013 Nov; 93(11):1232-40. PubMed ID: 24018792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response.
    Park DE; Cheng J; Berrios C; Montero J; Cortés-Cros M; Ferretti S; Arora R; Tillgren ML; Gokhale PC; DeCaprio JA
    Proc Natl Acad Sci U S A; 2019 Jan; 116(3):1027-1032. PubMed ID: 30598450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stochastic modeling and simulation of the p53-MDM2/MDMX loop.
    Cai X; Yuan ZM
    J Comput Biol; 2009 Jul; 16(7):917-33. PubMed ID: 19580521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mdmx promotes genomic instability independent of p53 and Mdm2.
    Carrillo AM; Bouska A; Arrate MP; Eischen CM
    Oncogene; 2015 Feb; 34(7):846-56. PubMed ID: 24608433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.